BCL2 and lymphoma: Whereas DHX9 was targeted in combination with ABT-737 treatment in the aforementioned Arf−/−Eμ-Myc/Bcl-2 lymphomas, it was found that loss of DHX9 on its own had a lethal effect on tumor cells where BCL-2 was not supra-elevated.